Wolters Kluwer Health has agreed to acquire AgileMD, a San Francisco-based healthcare technology company specializing in AI-powered clinical decision support, for up to $100 million. The transaction includes a $40 million upfront payment, with the remaining amount contingent on AgileMD meeting specific performance targets. The acquisition is expected to close in the first quarter of 2027, subject to customary closing conditions and regulatory approvals.
Founded in 2011, AgileMD offers interactive clinical pathways and predictive analytics designed to enhance care consistency and reduce mortality rates. Its flagship products include Pathways, which integrates local clinical guidelines into electronic health record (EHR) workflows, and eCART, an FDA-cleared AI-powered clinical surveillance tool aimed at real-time patient monitoring.
Wolters Kluwer Health, a global leader in healthcare information solutions, software, and services, plans to integrate AgileMD’s AI capabilities with its existing platforms, including the widely adopted UpToDate Expert AI. Since its launch in September 2025, UpToDate Expert AI has been implemented by over 2,700 U.S. hospitals and health systems, covering more than 95% of UpToDate Enterprise Edition customers in the country.
Yaw Fellin, Senior Vice President of Wolters Kluwer Clinical Solutions, stated, “Combined with UpToDate Expert AI and our partnerships, AgileMD will serve as a vital enabler for true UpToDate ubiquity in healthcare – facilitating UpToDate’s expansion into embedded workflows, local guidelines, and new digital health applications. With AgileMD, we are well positioned to help healthcare systems provide better patient care and extract more value from their tech investments.” Borna Safabakhsh, Co-Founder and CEO of AgileMD, added, “We are excited to join Wolters Kluwer Health. Coupled with UpToDate, AgileMD can more fully deliver its transformative impact in critical decision support workflows. Leveraging UpToDate’s foundational capabilities, AgileMD will accelerate and streamline the development and maintenance of more advanced clinical pathways for complex clinical decision-making support.”
AgileMD currently employs 23 staff members, all of whom will join Wolters Kluwer Health. The company is projected to reach $7 million in annual recurring revenue (ARR) by the end of 2026. Wolters Kluwer expects the acquisition to generate a return on invested capital (ROIC) at or above its after-tax weighted average cost of capital (WACC) of 8% within three to five years. The deal is anticipated to have an immaterial impact on Wolters Kluwer’s adjusted earnings.
The acquisition strengthens Wolters Kluwer Health’s position in the clinical decision support market by adding advanced AI-driven capabilities. It supports the company’s strategy to expand its healthcare IT offerings across the United States, Europe, and Asia-Pacific regions. Integration of AgileMD’s technology is expected to enhance clinical workflow automation, improve data interoperability, and accelerate product innovation cycles.
Industry experts note that this deal reflects a broader trend of consolidation in healthcare IT, with companies increasingly investing in AI to improve clinical decision-making and patient outcomes. Competitors may respond with increased M&A activity or strategic partnerships to bolster their AI capabilities.
Wolters Kluwer faces integration challenges including aligning AgileMD’s AI technology with existing platforms, managing cultural integration, and ensuring regulatory compliance across jurisdictions. Retaining key AgileMD talent will be critical to maintaining innovation momentum.
Looking ahead, Wolters Kluwer plans to leverage AgileMD’s AI tools to expand subscription and licensing revenue streams, develop new product offerings, and enhance the user experience for healthcare professionals. The acquisition underscores the growing importance of AI in healthcare and Wolters Kluwer’s commitment to advancing clinical decision support solutions.
